About Us

Few words about EgeBioScience

 

We started entrepreneurship for various diseases, especially cancer. Our aim as a biotechnology company is to discover innovative drug molecules for the diseases we target and to conduct extensive preclinical and clinical studies within our own company and/or in agreement with other relevant companies. As a result of the mutation of genes encoding proteins that play a role in cancer, new chemotherapy is required for each patient. For this, the patient’s genetic profile is primarily determined and the chemotherapy drug molecules applied are redesigned according to the mutated protein structure. Due to different gene mutations in different patients of the same disease, gene mutation classification studies will be carried out for that disease.

 

Artificial intelligence applications will provide innovative molecule design and discovery, together with human intelligence, in accordance with the different molecular structures of the same protein, which occurs in each patient as a result of gene profile classification.

 

Associate Professor Bülent Özpolat, M.D., Ph.D.

Extensive cancer and immunological studies, development-related mRNA vaccines, and drugs for various diseases (primarily cancer)

Texas University, MD ANDERSON CANCER CENTER, Houston TX USA.

Associate Professor, Ayşe Caner, M.D., Ph.D.

Ege University, School of Medicine, Head of Cancer Research Center, İzmir, Türkiye

Professor Erdem Büyükbingöl, Ph.D.

Retired Medicinal Chemist

Freelancer and Influencer on Drug Discovery and Artificial Intelligence

Ankara, Türkiye

Management Team

Bülent Özpolat
President
  1. Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene 39(4):801-813, 2020. e-Pub 2019. PMID: 31554935.
  2. Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond) 14(17):2315-2338, 2019. e-Pub 2019. PMID: 31432749.
  3. Pällmann N, Livgård M, Tesikova M, Zeynep Nenseth H, Akkus E, Sikkeland J, Jin Y, Koc D, Kuzu OF, Pradhan M, Danielsen HE, Kahraman N, Mokhlis HM, Ozpolat B, Banerjee PP, Uren A, Fazli L, Rennie PS, Jin Y, Saatcioglu F. Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. Oncogene 38(35):6301-6318, 2019. e-Pub 2019. PMID: 31312022.

Check more on MD ANDERSON CANCER CENTER website…

Ayşe Caner
CEO
  1. SRC Signaling in Cancer and Tumor Microenvironment, CANER A. , Asik E., Ozpolat B., TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT B, cilt.1270, ss.57-71, 2021.
  2. Targeting of antitumor ımmune responses with live-attenuated Leishmania strains in breast cancer model. Caner A. , Sadıqova A., Erdoğan A., Namlıses D., Nalbantsoy A., Oltulu F. , et al. Breast cancer (Tokyo, Japan), cilt.27, ss.1082-1095, 2020.
  3. Identification of gene expression profiles in Leishmania major infection by integrated bioinformatics analyses. Ulusan Ö., Mert U., Sadıqova A., Öztürk S., Caner A. Acta tropica, cilt.208, ss.105517, 2020.
  4. Intestinal Protozoan Parasitic Infections in Immunocompromised Child Patients with Diarrhea. Caner A. , Zorbozan O. , Tunalı V., Kantar M. , Aydoğdu S., Aksoylar S., et al. Japanese journal of infectious diseases, 2019.

 

 Check more Dr. Ayşe Caners’ publications…
Erdem Büyükbingöl
Scientific Advisor on Artificial Intelligence and Drug Discovery Progress
  1. Gilles KLOPMAN., Erdem BUYUKBINGOL., “An Artificial Intelligence Approach to the Study of the Structural Moieties Relevant to Drug-Receptor Interactions in Aldose Reductase Inhibitors”, Molecular Pharmacology, 34, 852-862 (1988).
  2. Sibel SUZEN, Erdem BUYUKBINGOL, “Anti-cancer Activity Studies of Indolalthiohydantoin (PIT) on Certain Cancer Cell Lines”, Farmaco, 55, 246-248 (2000).
  3. Sibel SUZEN, Erdem BUYUKBINGOL, “Recent Studies of Aldose Reductase Enzyme Inhibition for Diabetic Complications”, Current Medicinal Chemistry, 10, 1329-1353 (2003).
  4. ERDAS, Ozlem, ANDAC, Cenk, A., GURKAN-ALP, Selen, ALPARSLAN, Ferda, BUYUKBINGOL, Erdem, Compressed Images for Affinity Prediction (CIFAP): A Study on Predicting Binding Affinities for Checkpoint Kinase 1 Protein Inhibitors, J. Chemometrics, 27(6), 155-164, 2013.
  5. Ozlem Erdas-Cicek, Ali OsmanAtac, A. Selen Gurkan-Alp, Erdem Buyukbingol, Ferda Alpaslan, 3D Analysis of the Binding Sites for Predicting Binding Affinities in Drug Design, Journal of Chemical Information and Modeling, 59(11), 4654-4662 (2019). 2019.

Check more…

Research Scientists
  1. Molecular Biology and Genetics (A couple of candidates)
  2. Computer Engineers (A couple of candidates)
  3. Research Associates (Will be announced)